Related Experiment Video

Updated: Dec 6, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.5K

Bispecific Antibodies for Triple Negative Breast Cancer

Sundee Dees1, Rajkumar Ganesan1, Sanjaya Singh1

  • 1Janssen Biotherapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson, 1400 McKean Road, Spring House, PA 19477, USA.

Trends in Cancer
|October 12, 2020
PubMed

Insights

Triple negative breast cancer (TNBC) is aggressive and lacks key receptors. Novel bispecific antibodies offer a promising new immunotherapy approach for TNBC treatment.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Triple negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of ER, PR, and HER2 expression.
  • TNBC exhibits high metastatic potential and is associated with a poor prognosis, necessitating novel therapeutic strategies.
  • The immunogenic nature of TNBC presents an opportunity for developing targeted immunotherapies.

Purpose of the Study:

  • To review novel bispecific antibody therapeutics for triple negative breast cancer.
  • To discuss emerging therapeutic targets for future bispecific antibody development in TNBC.

Main Methods:

  • Literature review of current and emerging bispecific antibody therapies for TNBC.
  • Analysis of established clinical precedents for bispecific antibody treatments.

Main Results:

  • Bispecific antibody-based therapeutics are gaining attention for TNBC treatment.
  • Blinatumomab serves as a clinical precedent for bispecific T cell engagers in leukemia.

Conclusions:

  • Bispecific antibodies represent a promising avenue for TNBC immunotherapy.
  • Further research into novel targets will advance bispecific antibody development for TNBC.
Keywords:
T cell redirectionbispecific antibodiesbreast cancerimmunotherapytriple negative breast cancer

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.5K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K